Creative Biolabs has developed a cutting-edge platform utilizing phage display libraries, single B cell technologies, and hybridoma screening to accelerate the development of non-IgG antibodies like IgA, IgM, and IgE. Their bespoke services address technical challenges, optimize expression, and enhance therapeutic efficacy through humanization and glycoengineering techniques. Comprehensive quality characterization ensures the functionality and druggability of antibody candidates, positioning Creative Biolabs as a key player in advancing non-IgG antibodies for biomedical research.
